How the product works:
Recommended for:
Research:
Clinical studies (SURPASS, 2021–2022) demonstrated Tirzepatide’s superior efficacy compared to GLP-1 analogues in lowering HbA1c and body weight.
Indicated for the treatment of type 2 diabetes, improves glycaemic control, reduces the risk of complications, supports weight loss, and enhances metabolic health.
Administered as subcutaneous injections prescribed by a healthcare professional. Dosage and regimen are individual and depend on the patient’s condition and treatment response.
Side effects









